DE10214264A1 - HFA-Suspensionsformulierungen eines Anhydrats - Google Patents
HFA-Suspensionsformulierungen eines AnhydratsInfo
- Publication number
- DE10214264A1 DE10214264A1 DE10214264A DE10214264A DE10214264A1 DE 10214264 A1 DE10214264 A1 DE 10214264A1 DE 10214264 A DE10214264 A DE 10214264A DE 10214264 A DE10214264 A DE 10214264A DE 10214264 A1 DE10214264 A1 DE 10214264A1
- Authority
- DE
- Germany
- Prior art keywords
- hfa
- suspensions
- acid
- contain
- tiotropium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10214264A DE10214264A1 (de) | 2002-03-28 | 2002-03-28 | HFA-Suspensionsformulierungen eines Anhydrats |
MXPA04009338A MXPA04009338A (es) | 2002-03-28 | 2003-03-20 | Formulaciones de un anhidrato en suspension con hfa. |
BR0308709-3A BR0308709A (pt) | 2002-03-28 | 2003-03-20 | Formulações em suspensão de hfa de um anidrato |
EP03717219A EP1492498A2 (de) | 2002-03-28 | 2003-03-20 | Hfa-suspensionsformulierungen eines anhydrats |
PL03371295A PL371295A1 (en) | 2002-03-28 | 2003-03-20 | Hfa-suspension formulation of an anhydrate |
JP2003579782A JP5147158B2 (ja) | 2002-03-28 | 2003-03-20 | 無水物のhfa懸濁製剤 |
UA20041008758A UA79776C2 (en) | 2002-03-28 | 2003-03-20 | Hfa-suspension formulation of crystalline tiotropium bromide anhydrate and use thereof |
PCT/EP2003/002899 WO2003082244A2 (de) | 2002-03-28 | 2003-03-20 | Hfa-suspensionsformulierungen eines anhydrats |
MEP-2008-473A ME00246B (me) | 2002-03-28 | 2003-03-20 | Formulacije hfa-suspenzija koje sadrže anhidrat |
CNA038072475A CN1642525A (zh) | 2002-03-28 | 2003-03-20 | 无水化合物的hfa混悬剂 |
YU86004A RS52481B (en) | 2002-03-28 | 2003-03-20 | FORMULATION OF HFA-SUSPENSION CONTAINING ANHYDRATE |
EA200401159A EA008610B1 (ru) | 2002-03-28 | 2003-03-20 | Суспензионные препараты на основе кристаллического ангидрата тиотропийбромида |
KR1020047015174A KR101005717B1 (ko) | 2002-03-28 | 2003-03-20 | 무수물의 hfa-현탁 제형 |
AU2003221509A AU2003221509B2 (en) | 2002-03-28 | 2003-03-20 | HFA-suspension formulation of an anhydrate |
NZ536030A NZ536030A (en) | 2002-03-28 | 2003-03-20 | HFA-suspension formulation of crystalline tiotropium bromide anhydrate |
IL16369603A IL163696A0 (en) | 2002-03-28 | 2003-03-20 | Hfa-suspension formulation of an anhydrate |
CA2479638A CA2479638C (en) | 2002-03-28 | 2003-03-20 | Hfa-suspension formulations of crystalline tiotropium bromide anhydrate |
US10/400,127 US7244415B2 (en) | 2002-03-28 | 2003-03-26 | HFA suspension formulations of an anhydrate |
ZA2004/05637A ZA200405637B (en) | 2002-03-28 | 2004-07-15 | Hfa-suspension formulation of an anhydrate |
NO20044004A NO20044004L (no) | 2002-03-28 | 2004-09-23 | HFA-Suspensjonsformulering av et anhydrat |
HR20040890A HRP20040890A2 (en) | 2002-03-28 | 2004-09-27 | Hfa-suspension formulation of an anhydrate |
EC2004005322A ECSP045322A (es) | 2002-03-28 | 2004-09-28 | Formulaciones de un anhidrato en suspensión con hfa |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10214264A DE10214264A1 (de) | 2002-03-28 | 2002-03-28 | HFA-Suspensionsformulierungen eines Anhydrats |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10214264A1 true DE10214264A1 (de) | 2003-10-16 |
Family
ID=28050990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10214264A Withdrawn DE10214264A1 (de) | 2002-03-28 | 2002-03-28 | HFA-Suspensionsformulierungen eines Anhydrats |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1492498A2 (no) |
JP (1) | JP5147158B2 (no) |
KR (1) | KR101005717B1 (no) |
CN (1) | CN1642525A (no) |
AU (1) | AU2003221509B2 (no) |
BR (1) | BR0308709A (no) |
CA (1) | CA2479638C (no) |
DE (1) | DE10214264A1 (no) |
EA (1) | EA008610B1 (no) |
EC (1) | ECSP045322A (no) |
HR (1) | HRP20040890A2 (no) |
IL (1) | IL163696A0 (no) |
ME (1) | ME00246B (no) |
MX (1) | MXPA04009338A (no) |
NO (1) | NO20044004L (no) |
NZ (1) | NZ536030A (no) |
PL (1) | PL371295A1 (no) |
RS (1) | RS52481B (no) |
UA (1) | UA79776C2 (no) |
WO (1) | WO2003082244A2 (no) |
ZA (1) | ZA200405637B (no) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010138862A3 (en) * | 2009-05-29 | 2011-04-14 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
US8324266B2 (en) | 2009-05-29 | 2012-12-04 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
AU2018282272B2 (en) * | 2009-05-29 | 2020-05-14 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
US11471468B2 (en) | 2013-03-15 | 2022-10-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2007144531A (ru) * | 2005-05-02 | 2009-06-10 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Новые кристаллические формы тиотропийбромида |
AU2006243238B2 (en) * | 2005-05-02 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Novel crystalline forms of tiotropium bromide |
JP6781831B2 (ja) * | 2016-09-19 | 2020-11-04 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 医薬組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
EP1102579B1 (de) * | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
GB0009605D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
GB0009606D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
GB0009592D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
DE10113366A1 (de) * | 2001-03-20 | 2002-09-26 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten |
DE50115277D1 (de) * | 2000-10-31 | 2010-02-04 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen aus tiotropiumsalzen und |
DE10111058A1 (de) * | 2001-03-08 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten |
-
2002
- 2002-03-28 DE DE10214264A patent/DE10214264A1/de not_active Withdrawn
-
2003
- 2003-03-20 ME MEP-2008-473A patent/ME00246B/me unknown
- 2003-03-20 CA CA2479638A patent/CA2479638C/en not_active Expired - Fee Related
- 2003-03-20 RS YU86004A patent/RS52481B/en unknown
- 2003-03-20 UA UA20041008758A patent/UA79776C2/uk unknown
- 2003-03-20 CN CNA038072475A patent/CN1642525A/zh active Pending
- 2003-03-20 BR BR0308709-3A patent/BR0308709A/pt active Pending
- 2003-03-20 AU AU2003221509A patent/AU2003221509B2/en not_active Expired
- 2003-03-20 MX MXPA04009338A patent/MXPA04009338A/es active IP Right Grant
- 2003-03-20 NZ NZ536030A patent/NZ536030A/en not_active IP Right Cessation
- 2003-03-20 KR KR1020047015174A patent/KR101005717B1/ko active IP Right Grant
- 2003-03-20 EA EA200401159A patent/EA008610B1/ru unknown
- 2003-03-20 IL IL16369603A patent/IL163696A0/xx unknown
- 2003-03-20 EP EP03717219A patent/EP1492498A2/de not_active Withdrawn
- 2003-03-20 WO PCT/EP2003/002899 patent/WO2003082244A2/de active Application Filing
- 2003-03-20 JP JP2003579782A patent/JP5147158B2/ja not_active Expired - Lifetime
- 2003-03-20 PL PL03371295A patent/PL371295A1/xx not_active Application Discontinuation
-
2004
- 2004-07-15 ZA ZA2004/05637A patent/ZA200405637B/en unknown
- 2004-09-23 NO NO20044004A patent/NO20044004L/no not_active Application Discontinuation
- 2004-09-27 HR HR20040890A patent/HRP20040890A2/hr not_active Application Discontinuation
- 2004-09-28 EC EC2004005322A patent/ECSP045322A/es unknown
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010138862A3 (en) * | 2009-05-29 | 2011-04-14 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
WO2010138884A3 (en) * | 2009-05-29 | 2011-04-21 | Pearl Therapeutics, Inc. | Respiratory delivery of active agents |
WO2010138868A3 (en) * | 2009-05-29 | 2011-04-28 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems |
CN102596176A (zh) * | 2009-05-29 | 2012-07-18 | 珍珠治疗公司 | 经呼吸递送活性剂的组合物及相关方法和系统 |
US8324266B2 (en) | 2009-05-29 | 2012-12-04 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
US8703806B2 (en) | 2009-05-29 | 2014-04-22 | Pearl Therapeutics, Inc. | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
US8808713B2 (en) | 2009-05-29 | 2014-08-19 | Pearl Thereapeutics, Inc. | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
AU2010253770B2 (en) * | 2009-05-29 | 2014-12-11 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
AU2010253776B2 (en) * | 2009-05-29 | 2015-01-22 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems |
US9415009B2 (en) | 2009-05-29 | 2016-08-16 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
US9463161B2 (en) | 2009-05-29 | 2016-10-11 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
AU2018282272B2 (en) * | 2009-05-29 | 2020-05-14 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
US10716753B2 (en) | 2009-05-29 | 2020-07-21 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
RU2751771C2 (ru) * | 2009-05-29 | 2021-07-16 | Перл Терапьютикс, Инк. | Композиции для респираторной доставки активных веществ и связанные с ними способы и системы |
US11471468B2 (en) | 2013-03-15 | 2022-10-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
Also Published As
Publication number | Publication date |
---|---|
BR0308709A (pt) | 2005-01-04 |
JP2005527550A (ja) | 2005-09-15 |
UA79776C2 (en) | 2007-07-25 |
JP5147158B2 (ja) | 2013-02-20 |
HRP20040890A2 (en) | 2005-06-30 |
RS52481B (en) | 2013-02-28 |
MXPA04009338A (es) | 2005-01-25 |
NZ536030A (en) | 2006-07-28 |
AU2003221509A1 (en) | 2003-10-13 |
EP1492498A2 (de) | 2005-01-05 |
CN1642525A (zh) | 2005-07-20 |
AU2003221509B2 (en) | 2008-01-24 |
ZA200405637B (en) | 2005-07-27 |
KR101005717B1 (ko) | 2011-01-05 |
WO2003082244A2 (de) | 2003-10-09 |
IL163696A0 (en) | 2005-12-18 |
CA2479638C (en) | 2011-01-04 |
PL371295A1 (en) | 2005-06-13 |
MEP47308A (en) | 2011-02-10 |
ECSP045322A (es) | 2005-01-28 |
EA200401159A1 (ru) | 2005-04-28 |
ME00246B (me) | 2011-05-10 |
EA008610B1 (ru) | 2007-06-29 |
CA2479638A1 (en) | 2003-10-09 |
WO2003082244A3 (de) | 2004-02-05 |
KR20040098022A (ko) | 2004-11-18 |
YU86004A (sh) | 2006-08-17 |
NO20044004L (no) | 2004-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1809243B1 (de) | Aerosolsuspensionsformulierungen mit tg 227 ea als treibmittel | |
EP1326862B1 (de) | Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels | |
EP0843676B1 (de) | Arzneimittelvorbereitungen enthaltend ein enantiomer von ipratropiumbromid mit verlängerter wirkungsdauer | |
EP1514546B1 (de) | Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols | |
EP1682542B1 (de) | Neues kristallines anhydrat mit anticholinerger wirksamkeit | |
WO1993018746A1 (de) | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten | |
US20080044361A1 (en) | HFA Suspension Formulations Containing an Anticholinergic | |
EP1492513B1 (de) | Hfa-suspensionsformulierungen enthaltend ein anticholinergikum | |
EP2083007A1 (de) | Tiotropiumsalze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittelformulierungen | |
DE10214264A1 (de) | HFA-Suspensionsformulierungen eines Anhydrats | |
EP1682541B1 (de) | Verfahren zur herstellung von tiotropiumsalzen | |
US7244415B2 (en) | HFA suspension formulations of an anhydrate | |
DE102004032322A1 (de) | Aerosolsuspensionsformulierungen mit TG 227 ea als Teibmittel | |
DE10209243A1 (de) | Neue Arzneimittelkombination zur Inhalation | |
DE10145438A1 (de) | Neue Arzneimittel zur Inhalation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8141 | Disposal/no request for examination |